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6/j.bSevere keratinocyte dysplasia (SKD) has been reported as a common event in the early posttransplantation
period of hematopoietic stem cell transplantation patients. The purpose of our study is to determine the
possible causes of SKD during the intermediate posttransplantation period and to ascertain its prevalence
in skin biopsies. Skin biopsy slides, obtained from hematopoietic stem cell transplantation recipients who
were days 28 to 84 posttransplantation, were evaluated for SKD. Forty-four examples of SKDwere identified
in 467 slides, or 9%. Thirty-seven patients were evaluated as cases in a case-control design. SKDwas strongly
associated with a conditioning regimen containing busulfan with an odds ratio of 7.25 (P 5 .0002). In a
multivariate-adjusted analysis, SKD was not associated with cyclophosphamide, fludarabine, total-body irra-
diation, or a nonmyeloablative conditioning regimen. SKDwas not associated with clinical acute graft-versus-
host disease. SKD histology gradually resolved, reaching a normal histology after an average of 241 days. This
study finds that severe keratinocyte dysplasia in the period 28 to 84 days post-HSCT is strongly associated
with a busulfan-conditioning regimen.
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(HSCT) recipients, we noted the sporadic appearance,
in skin biopsies, of severe keratinocyte dysplasia
(SKD). The histologic appearance seems distinct
from graft-versus-host disease (GVHD). SKD is char-
acterized by large keratinocytes with large and often ir-
regular nuclei. GVHD is typically characterized by
apoptotic keratinocytes and a lymphoid infiltrate.
SKD has been described as a common, albeit
poorly documented, effect of chemotherapy in the
nontransplantation population, and there is a sugges-
tion that it is associated with drugs that can disruptpartment of Pathology, University of Washington
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There are 2 reports of skin dysplasia in marrow
transplantation recipients. Casta~no et al. [1] found
that severe keratinocyte dysplasia is a frequent histo-
logic finding in patients who have had a bone marrow
or liver transplantation within 60 days posttransplanta-
tion, being present in 40.9% of this mixed population.
Although some of the cases occurred in the absence of
any chemotherapy, pretreatment with the alkylating
agent cyclophosphamide was found to be the only in-
dependent chemotherapeutic agent significantly asso-
ciated with a higher risk of severe dysplasia.
In contrast, Hymes et al. [3] found the incidence of
severe keratinocyte dysplasia to be 92% in marrow
transplantation recipients prepared with the alkylating
agent busulfan. SKD was restricted to the interval
15 to 45 days posttransplantation. They further specu-
lated that mild keratinocyte dysplasia early posttr-
ansplantation, with a median of 13 days, was because
of cyclophosphamide.
We observed significant numbers of severe dyspla-
sia in skin biopsies of patients more than 3 weeks post-
HSCT.We set out to determine the incidence of SKD
in the posttransplantation period from 28 to 84 days
and to find any association with chemotherapeutic
agents, transplantation type, or GVHD.1281
Figure 1. (A) Severe keratinocyte dysplasia (SKD) and GVHD in a patient 35 days posttransplantation. The skin exhibits enlarged cells, enlarged nuclei,
irregular nuclear contours, and prominent nucleoli. Keratohyaline granules are prominent. A fragmenting nucleus may be seen in the midepidermis on
the left. This skin additionally shows evidence of GVHD, with a lymphocyte (large arrow), an apoptotic cell (small arrow), and abundant lymphocytes in
the dermis. (B) SKD in a patient 77 days posttransplantation. There is epidermal atrophy, along with the features of SKDof enlarged cells, enlarged nuclei,
and prominent nucleoli.
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Case Identification
We constructed a case-control study using skin bi-
opsy slides from the Fred Hutchinson Cancer Research
Center-SeattleCancerCareAlliance, Seattle,Washing-
ton. All skin biopsy slides from 2002 and 2003 that had
been obtained from 28 to 84 days after HSCT were ex-
amined, including autografts and nonmyeloablative
transplantations. Most of the skin biopsies were ob-
tained to evaluate the possible presence of cutaneous
GVHD. The biopsies were reexamined blindly without
knowledge of clinical data or histologic diagnosis.
The stained slides were examined for evidence of
keratinocyte dysplasia, which is characterized by dis-
ruption of the normal keratinocyte maturation with
enlarged cells, enlarged nuclei, irregular nuclear con-
tours, prominent nucleoli, multinucleation, as well as
frequent normal and abnormal mitotic figures. The
process can be focal, multifocal, or diffuse, with partial
or full epidermal thickness involvement. Only the
slides with SKD were included in our study, which is
defined as dysplastic keratinocytes that have enlarged
nuclei at least twice the diameter of normal cell nuclei,
and the extent of dysplasia is at least multifocal, with
involvement of the superficial spinous layers.Case and Control Selection Criteria
A 1:2 case-control design was employed. Only
slides from patients following the first HSCT were el-
igible for the study, and slides from patients after sec-
ond or third transplantations were excluded. Cases
consisted of all patients with a slide showing severe
keratinocyte dysplasia. If a patient had slides showing
SKD on more than one date, the slide from the latest
date was chosen as the case slide. Two control patients
were selected for each case from the set of patients who
never showed SKD in a skin biopsy from days 28 to 84.
Controls were matched to cases according to days
posttransplantation and age {minimum of [(absolute
value of difference in days posttransplantation) plus(absolute value of difference in age in years)]}, and
each control patient was chosen only once.
GVHD Evaluation
All the case and control slides were examined for
histologic evidence of acute GVHD (aGVHD) (histo-
logic GVHD) by staff unaware of clinical characteris-
tics or diagnosis. GVHD was graded according to the
grading system of Sale et al. [4,5], which requires
dyskeratotic keratinocytes (apoptotic cells,
‘‘eosinophilic bodies’’) in numbers excessive for site,
usually but not invariably associated with exocytosis
of lymphocytes in the epidermis, the presence of
lymphocytes in the dermis, and basal vacuolar
changes. Clinical aGVHD (clinical GVHD) was
assessed based on overall severity in all organs by
a standard system of evaluation [6]. The evaluation
of clinical GVHD did not include any histology infor-
mation. Only histologic and clinical grades 2, 3, and 4
(out of 4) were considered positive for aGVHD for the
purposes of our study. The relationships between SKD
and donor and patient factors were analyzed using con-
ditional logistic regression, stratified on each case-
control set.
Evaluation of Course
To determine the course of SKD, all available sub-
sequent skin biopsies of the cases were examined and
evaluated for dysplasia and less severe changes.RESULTS
Frequency Determination, Case and Control
Selection
A total of 467 skin biopsies were examined. They
derived from 352 individuals. Each biopsy was assessed
for severe keratinocyte dysplasia (Figure 1). The rate
of SKD was 9% of the skin biopsies (44 of 467 skin bi-
opsies) and 12% of the biopsied individuals (41 of 352
individuals). Excluding multiple biopsies from the
Table 1. Univariate Risk Factors for Severe Keratinocyte Dysplasia
Controls N (%) Cases N (%) OR (95% CI) P value
Gender
Female 31 (42%) 17 (46%) 1.0 .67
Male 43 (58%) 20 (54%) 0.84 (0.4-1.9)
Donor type
Matched sib 24 (32%) 12 (32%) [1.0] .99
Unrelated 42 (57%) 21 (57%) 1.00 (0.4-2.5)
Autologous 4 (5%) 2 (5%) 1.00 (0.2-6.6)
Other related 4 (5%) 2 (5%) 1.00 (0.2-5.9)
Diagnosis
AML 32 (43%) 12 (32%) [1.0] .002
CML 9 (12%) 2 (5%) 0.58 (0.1-3.2)
MDS 17 (23%) 21 (57%) 3.16 (1.2-8.1)
Other 16 (22%) 2 (5%) 0.28 (0.1-1.4)
Conditioning
Busulfan in conditioning regimen
No 36 (49%) 6 (16%) 1.0 .0002
Yes 38 (51%) 31 (84%) 7.25 (2.1-25)
Cytoxan in conditioning regimen
No 22 (30%) 5 (14%) 1.0 .02
Yes 52 (70%) 32 (86%) 4.21 (1.1-16)
Fludarabine in conditioning regimen
No 54 (73%) 34 (92%) [1.0] .004
Yes 20 (27%) 3 (8%) 0.15 (0.0-0.7)
TBI in conditioning regimen
None 42 (57%) 31 (42%) 1.0 .007
200 cGy 16 (22%) 2 (6%) 0.14 (0.0-0.7)
>200 cGy 16 (22%) 3 (8%) 0.32 (0.1-1.2)
Nonmyeloablative conditioning
No 58 (78%) 35 (95%) 1.0 .009
Yes 16 (22%) 2 (5%) 0.16 (0.0-0.8)
GVHD
Clinical acute GHVD (grade 2-4)
No 22 (30%) 9 (24%) 1.0 .53
Yes 52 (70%) 28 (76%) 1.35 (0.5-3.4)
Histologic GVHD (grade 2-4)
No 29 (39%) 8 (22%) 1.0 .05
Yes 45 (61%) 29 (78%) 2.61 (1.0-7.0)
AML indicates acute myellogenous leukemia; CML, chronic myeloid leukeima; MDS, myelodysplastic syndrome.
Biol Blood Marrow Transplant 18:1281-1286, 2012 1283Severe Keratinocyte Dysplasiasame patient (3) and second and third transplantations
(4), 37 cases were identified. Seventy-four age and day
posttransplantation matched controls were assigned
in the 1:2 design. The mean age of cases was 49.6 years
and of controls 49.3 years. The mean day of biopsy
posttransplantation was 61.0 days for cases and 60.9
days for controls.
Univariate Risk Factors for SKD
The univariate risk factors for severe keratinocyte
dysplasia are presented in Table 1. Donor type, whether
a matched sibling, an unrelated donor, or an autologous
donor was not associated with SKD. The diagnosis of
myelodysplastic syndrome, which also includes non-
chronic myeloid leukeima myeloproliferative neoplasms
and myelodysplastic/myeloproliferative neoplasms,
was significantly associated with SKD in the univariate
analysis (P5 .002), with an odds ratio (OR) of 3.16 com-
pared with acute myeloid leukemia. The conditioning
regimen was also significantly associated with SKD,
with a busulfan-containing regimen showing an OR of
7.25 (P 5 .0002) compared with regimens without
busulfan. A cytoclophosphamide-containing regimen
was also significantly associated with SKD (OR, 4.21;P5 .02). A fludarabine-containing regimen was signifi-
cantly associated with a lower risk of SKD (OR, 0.15;
P5 .004). Total-body irradiation (TBI) was also associ-
ated with a lower risk of SKD (P 5 .007), with the
application of the low level of radiation, 200 cGy, show-
ing significancewith anORof0.14.Bothfludarabine and
200 cGyofTBI are typically restricted to nonmyeloabla-
tive transplantations. Any nonmyeloablative condition-
ing regimen was similarly significantly negatively
associated with SKD (OR, 0.16; P5 .009).Multivariate Risk Factors for SKD
To determine what factors were independently as-
sociated with SKD, a multivariate model was adopted.
After adjustment for the use of busulfan, none of the
other conditioning-related factors or the diagnoses
was significantly associated with SKD (Table 2).
Conversely, the use of busulfan remained significant
even after adjustment for these factors. Thus, the
apparent associations of SKD with cyclophosphamide,
fludarabine, TBI, nonmyeloablative conditioning, and
diagnosis are largely explained by the degree to which
these factors are associated with the use of busulfan.
Table 2. Multivariate Analysis Adjusting for the Presence of
Busulfan in the Conditioning Regimen
Adjusteda
OR (95% CI) P value
Diagnosis
AML [1.0] .24
CML 0.49 (0.1-2.7)
MDS 2.00 (0.7-5.7)
Other 0.46 (0.1-2.7)
Conditioning
Cytoxan in conditioning regimen
No [1.0] .63
Yes 1.44 (0.3-6.6)
Fludarabine in conditioning regimen
No [1.0] .30
Yes 0.41 (0.1-2.4)
TBI in conditioning regimen
None [1.0] .20
200 cGy Undefined
>200 cGy Undefined
Nonmyeloablative conditioning
No [1.0] .49
Yes 0.51 (0.1-3.4)
CML indicates chronic myeloid leukemia; MDS, myelodysplastic
syndrome.
aEach factor adjusted for busulfan in conditioning regimen.
Table 3. Histologic GVHD in Patients without Clinical
aGVHD, Stratified According to Busulfan Treatmenta
Histologic GHVD
GVHD (% of row) No GVHD
Busulfan 10 (67%) 5
No busulfan 5 (50%) 5
aAutografts are excluded.
1284 Biol Blood Marrow Transplant 18:1281-1286, 2012N. Li et al.GVHD and SKD
There was no evidence that clinical GVHD, as as-
sessed without involving pathology data, is associated
with SKD (Table 1).
The possible presence of histologic GVHD was
evaluated in the same skin slide as examined for SKD.
The evaluation of GVHD in the SKD cases proved
problematic, with difficulty applying the criteria for
GVHD diagnosis in skin with a background of large,
dysplastic keratinocytes, which might be expected to
show more apoptotic cells than normal skin. The uni-
variate analysis showed that SKD was associated with
GVHD (OR, 2.61; P 5 .05) (Table 1).
It is possible that busulfan is associated with both
SKD and GVHD-like histologic changes in skin but
is not actually related to clinical GVHD. This would
result in the association of busulfan with ‘‘histologic
GVHD’’ but not clinical GVHD. To study this possi-
bility, only those patients without clinical GVHD
were examined, with the 6 autologous patients ex-
cluded. The presence or absence of histologic GVHD
was stratified for the presence or absence of busulfan
treatment (Table 3). Histologic GVHDwas not signif-
icantly associatedwith busulfan,with 67%of thosewith
busulfan showingGVHD, comparedwith50%of those
withnobusulfan (P5 .55, Fisher exact test).Thesefind-
ings do not support busulfan as an agent related to the
diagnosis of histologic GVHD.
Evaluation of Course of SKD
To approximate the course of SKD, subsequent
skin biopsies were examined. The first available biopsy
subsequent to the biopsy showing SKD was evaluated.These were often beyond the 84-day posttransplanta-
tion criterion used for initial inclusion in the study.
Twenty-nine cases were available. SKD was found in
none of them. The appearance ranged from a lesser de-
gree of keratinocyte dysplasia not reaching the criteria
for SKD (7%), to the less damaged moderate keratino-
cyte atypia exhibiting prominent nucleoli (21%), to
slight keratinocyte atypia exhibiting visible nucleoli
(52%), to normal (21%). The interval from the time
of the SKD biopsy averaged 32, 45, 193, and 241
days, for each appearance type, respectively. These
findings suggest that SKD starts resolving within a pe-
riod of 32 days but reaches normal morphology many
months later, averaging 241 days.
Incidence of SKD
To estimate the frequency of busulfan-associated
SKD in the biopsied patients, we calculated an inci-
dence rate in the individuals prepared with busulfan.
Approximately 199 patients were treated with busulfan
(extrapolating from the fraction of treated controls and
cases), resulting in 31 busulfan-associated SKD cases
(Table 1). This suggests, in biopsied patients condi-
tioned with busulfan, 16% developed SKD in the
day-28-to-84 posttransplantation interval.DISCUSSION
We investigated severe keratinocyte dysplasia in
day 28 to 84 of the posttransplantation period in
a case-control study. This design is well suited for
ascertaining possible associations with pretransplanta-
tion factors. In a multivariate model, a preparative
regimen containing busulfan was strongly associated
with SKD.
Theprevalenceof SKDwas9%of thebiopsies, 12%
of theHSCTrecipients, and16%of thosepreparedwith
busulfan. Those studied were limited to patients who
underwent skin biopsies in the day-28-to-84 time period
and represent about half the patients who underwent
transplantation. Skin biopsies are often taken of clinical
lesions and are routinely takenwith or without lesions at
departure or about day 80 posttransplantation. There-
fore, these estimates only provide approximate frequen-
cies based on a large number of skin biopsies and do not
provide precise population-based frequencies. The cal-
culated prevalence of busulfan-associated SKD may be
subject to further slight inaccuracy because of the
Biol Blood Marrow Transplant 18:1281-1286, 2012 1285Severe Keratinocyte Dysplasiasampling variance of controls and the inclusion of cen-
sored individuals such as second transplantation recipi-
ents. Nevertheless, the estimated 16% incidence in
busulfan-treated patients is the most reliable available
for this pathological finding.
Keratinocyte dysplasia following chemotherapy has
been described infrequently but is now well docu-
mented to actually occur at high frequencies. It has
been variously described as keratinocyte atypia, kerati-
nocyte dysmaturation, or epidermal dysmaturation
[2]. The cause of the epidermal dysmaturation has
been postulated to be a direct cytotoxic action of che-
motherapeutic drugs or radiation given before engraft-
ment, affecting keratinocytes [2]. In patients who have
not undergone transplantation, these agents have been
associated with a specific skin pathology exhibiting an
attenuated epidermis, individual keratinocyte necrosis,
and cell-poor interface dermatitis [7-9]. The agents
include cyclophosphamide, busulfan, cyclosporine,
etoposide, docetaxel, thiotepa, cytarabine, bleomycin,
hydroxyurea, methotrexate, and others.
Etoposide and busulfan have been associated with
specific pathologic abnormalities [3,7,10]. The specific
keratinocyte pathology associated with busulfan has
been described as ‘‘‘busulfan’ cells that are abnormally
large keratinocytes with extremely large nuclei.
[that] demonstrate irregular nuclear contours, bizarre
chromatin patterns, and prominent keratohyaline
granules’’ [7]. This description is similar to, but gener-
ally more marked than, our independently determined
criteria defining severe keratinocyte dysplasia.
The severe form of keratinocyte dysplasia has been
described in posttransplantation patients as a common
lesion, more frequent early posttransplantation [1,3,4].
Casta~no et al. [1] reported a 44% incidence of severe
keratinocyte dysplasia in the post-marrowor liver trans-
plantation recipients in theperiod less than60dayspost-
transplantation.They found an independent association
with cyclophosphamide and not busulfan.
Hymes et al. [3] found the incidence of severe kera-
tinocyte dysplasia to be 92% in busulfan-treated mar-
row transplantation recipients in the interval 15 to 45
days posttransplantation. Because the dose of busulfan
was similar to ours (total, 16mg/kg), onepossible expla-
nation of the markedly higher incidence is the earlier
procurement of the skin biopsies.Withweekly biopsies,
virtually all of their cases would have been biopsied
twice in the 15-to-27-day period, during which they
could have found SKD. Our patients were biopsied on
day 28 at the earliest.The interval difference is reflected
in their median day posttransplantation of 35, versus
our mean of 61. They further separated out slight
dysplasia present early posttransplantation, median
13 days, and ascribed it to the cyclophosphamide in
aTBI-cyclophosphamide regimen, as had Sale et al. [4].
The most likely explanation is that cyclophospha-
mide is commonly associated with slight keratinocytedysplasia early posttransplantation, and busulfan is
commonly associated with severe keratinocyte dyspla-
sia, lasting in some smaller number of cases, later into
the posttransplantation period.
One of the challenges presented by chemotherapy
toxicity occurring after marrow transplantation is its
histologic similarity to skin GVHD [4,11]. However,
chemoradiation toxicity was not associated with
findings diagnostic of histologic GVHD after 20 days
posttransplantation [4,12]. Others have also found
that keratinocyte dysplasia was not associated with
the onset of aGVHD [1,3].
Our data suggest that SKD is not associated with
clinical GVHD but is associated with histologic
GVHD (OR, 2.61; P 5 .05). It is evident from
Table 3 that a busulfan preparative regimen fails to
be associated with histologic GVHD. This leaves
open the possibility that histologic GVHD may tend
to be diagnosed in the presence of concurrent SKD.
Table 3 also implies that histologic GVHD was some-
times diagnosed in the absence of clinicalGVHD.This
is a widely reported phenomenon, presumably because
of the relatively low specificity of the histologic criteria
[7,13,14]. Further conclusions regarding GVHD are
beyond the power of this case-control study of SKD.
‘‘What happens to severe keratinocyte dysplasia?’’
The time course of SKDwas studied by evaluating sub-
sequent skin biopsies, when available. A statistical
treatment was not attempted. It turned out that SKD
resolved rapidly, appearing as slight dysplasia in
32 days on average and moderate atypia in 45 days.
Normal histology was reached only slowly, however,
after an average of 241 days following the index biopsy.
The conclusion that SKD reverts gradually to normal
histology over several months is warranted.
In summary, our study has provided evidence that
severe keratinocyte dysplasia is an occasional histologic
finding in day 28 to 84 of the posttransplantation period
of HSCT patients, with a frequency of 9% of the biop-
sies, 12% of the biopsied patients, and 16% of biopsied
patients preparedwith abusulfan-containingcondition-
ing regimen. Preparation for transplantation with bu-
sulfan was independently and very strongly associated
with SKD. Familiarity with this potential association
is important for the correct diagnosis when evaluating
biopsies from this particular patient population.ACKNOWLEDGMENTS
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